Media coverage about NovoCure Limited (NASDAQ:NVCR) has been trending somewhat negative this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NovoCure Limited earned a media sentiment score of 0.00 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 47.2297718867715 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media headlines that may have impacted Accern’s rankings:
- NovoCure Limited (NVCR) registers a price change of 4.10% while Galmed Pharmaceuticals Ltd. (GLMD) finishes with … – Stocks Gallery (stocksgallery.com)
- A Side-by-side Analysis of NovoCure Limited (NVCR) and Accuray Incorporated (ARAY) – StockNewsGazette (stocknewsgazette.com)
- Changes in Signals Identified: NovoCure Limited (NVCR), Cloud Peak Energy Inc. (CLD) – AllStockNews (allstocknews.com)
- NovoCure Limited (NVCR) Insider bought 354780 Shares – Economic News (economicsandmoney.com)
- Stocks; In Focus: Majesco, Corcept Therapeutics, MiMedx And Supernus – Investing.com (investing.com)
Several research firms have commented on NVCR. Zacks Investment Research lowered shares of NovoCure Limited from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. BidaskClub lowered shares of NovoCure Limited from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Wedbush reissued an “outperform” rating and issued a $20.00 target price on shares of NovoCure Limited in a report on Thursday, April 27th. Deutsche Bank AG reissued a “hold” rating and issued a $19.00 target price (up from $18.00) on shares of NovoCure Limited in a report on Monday, July 17th. Finally, ValuEngine raised shares of NovoCure Limited from a “sell” rating to a “hold” rating in a report on Saturday, June 3rd. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $19.29.
Shares of NovoCure Limited (NASDAQ:NVCR) opened at 18.85 on Friday. NovoCure Limited has a 1-year low of $5.95 and a 1-year high of $21.75. The stock has a 50 day moving average of $18.94 and a 200-day moving average of $12.66. The firm’s market capitalization is $1.68 billion.
NovoCure Limited (NASDAQ:NVCR) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.01. The company had revenue of $38.38 million during the quarter, compared to the consensus estimate of $42.20 million. NovoCure Limited had a negative return on equity of 69.48% and a negative net margin of 75.91%. On average, equities analysts expect that NovoCure Limited will post ($0.75) earnings per share for the current year.
In other NovoCure Limited news, CEO Asaf Danziger sold 7,383 shares of the stock in a transaction that occurred on Tuesday, July 11th. The shares were sold at an average price of $19.95, for a total transaction of $147,290.85. Following the transaction, the chief executive officer now directly owns 462,765 shares in the company, valued at $9,232,161.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Yoram Palti sold 8,000 shares of the stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $11.73, for a total transaction of $93,840.00. Following the transaction, the insider now owns 35,825 shares in the company, valued at $420,227.25. The disclosure for this sale can be found here. Insiders have sold 2,253,522 shares of company stock worth $38,336,772 over the last quarter. Company insiders own 16.70% of the company’s stock.
NovoCure Limited Company Profile
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.
Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.